Treatment of Uterine Sarcoma in Uterine Leiomyosarcoma

Clinical Scenario

Uterine leiomyosarcoma (uLMS) is the principal subgroup of uterine sarcomas. This protocol addresses patients with uterine leiomyosarcoma presenting with locally advanced disease (FIGO stages II–III).

Treatment Approach

For locally advanced uterine leiomyosarcoma, the structured approach involves chemotherapy — timed relative to surgery according to disease stage and surgical resectability — with radiotherapy considered in select clinical situations. The complete regimen, sequencing, and eligibility criteria are available in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1136/ijgc-2024-005823

uLMS are the main subgroup of uterine sarcomas.
Post-operative chemotherapy can be considered (V, B).
Pre-operative chemotherapy for stage III disease with doxorubicin+trabectedin (I, B) or doxorubicin+dacarbazine is recommended in an effort to improve surgical resectability (IV, B).
Pelvic radiotherapy may be an alternative option as definitive treatment if surgery is not feasible or after incomplete pelvic surgery (R1/R2) (IV, C).
Post-operative radiotherapy can be considered in high-grade LMS with involvement of cervix/parametria and/or positive margins (IV, C).

View source ↗